| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748382 | RADIUS | Method of drug delivery for bone anabolic protein |
Oct, 2027
(3 years from now) | |
| US8148333 | RADIUS | Stable composition comprising a PTHrP analogue |
Nov, 2027
(3 years from now) | |
| US7803770 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(7 years from now) | |
| USRE49444 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(7 years from now) | |
| US10996208 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(14 years from now) | |
| US11782041 | RADIUS | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
Apr, 2038
(14 years from now) | |
| US11255842 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(15 years from now) | |
| US11680942 | RADIUS | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
Jan, 2040
(15 years from now) | |
Tymlos is owned by Radius.
Tymlos contains Abaloparatide.
Tymlos has a total of 8 drug patents out of which 0 drug patents have expired.
Tymlos was authorised for market use on 28 April, 2017.
Tymlos is available in solution;subcutaneous dosage forms.
Tymlos can be used as use for detecting neutralizing antibodies, method of treating postmenopausal women with osteoporosis at high risk for fracture., treatment to increase bone density in men with osteoporosis at high risk for fracture.
Drug patent challenges can be filed against Tymlos from 28 April, 2021.
The generics of Tymlos are possible to be released after 10 January, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture; Use for detecting neutraliz...
Dosage: SOLUTION;SUBCUTANEOUS
TYMLOS family patents
